Cargando…

Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis

We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who...

Descripción completa

Detalles Bibliográficos
Autores principales: Dermitzakis, Emmanouil V., Vikelis, Michail, Vlachos, George S., Argyriou, Andreas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145697/
https://www.ncbi.nlm.nih.gov/pubmed/35622543
http://dx.doi.org/10.3390/toxins14050296
_version_ 1784716378868023296
author Dermitzakis, Emmanouil V.
Vikelis, Michail
Vlachos, George S.
Argyriou, Andreas A.
author_facet Dermitzakis, Emmanouil V.
Vikelis, Michail
Vlachos, George S.
Argyriou, Andreas A.
author_sort Dermitzakis, Emmanouil V.
collection PubMed
description We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who completed three consecutive cycles of treatment, according to the standard PREEMPT paradigm. Participants were classified to those scheduled to be treated in the morning hours from 8:00 to 12:00 (AM) or afternoon hours from 13:00 to 18:00 (PM). We then assessed and compared between groups the changes from baseline (T0—trimester before BoNTA’s first administration) to the period after its third administration (T3) in the following efficacy outcomes: (i) mean number of headache days/month, (ii) mean number of days/month with peak headache intensity of >4/10, (iii) mean number of days/month with consumption of any abortive treatment. Safety–tolerability was also compared between groups. Results: A total of 50 AM and 50 PM-treated patients were evaluated. The within-group analysis in both groups showed a significant decrease in all efficacy variables between T0 and T3. However, the between-group comparisons of all BoNTA-related efficacy outcomes at T3 vs. T0 documented comparable improvements between AM vs. PM-treated patients. Safety/tolerability was also similar between groups. Conclusions: We were not able to identify significant differences between patients treated in the AM vs. PM, so as to demonstrate that the circadian time of administration should be considered before initiating BoNTA in CM patients.
format Online
Article
Text
id pubmed-9145697
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91456972022-05-29 Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis Dermitzakis, Emmanouil V. Vikelis, Michail Vlachos, George S. Argyriou, Andreas A. Toxins (Basel) Article We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who completed three consecutive cycles of treatment, according to the standard PREEMPT paradigm. Participants were classified to those scheduled to be treated in the morning hours from 8:00 to 12:00 (AM) or afternoon hours from 13:00 to 18:00 (PM). We then assessed and compared between groups the changes from baseline (T0—trimester before BoNTA’s first administration) to the period after its third administration (T3) in the following efficacy outcomes: (i) mean number of headache days/month, (ii) mean number of days/month with peak headache intensity of >4/10, (iii) mean number of days/month with consumption of any abortive treatment. Safety–tolerability was also compared between groups. Results: A total of 50 AM and 50 PM-treated patients were evaluated. The within-group analysis in both groups showed a significant decrease in all efficacy variables between T0 and T3. However, the between-group comparisons of all BoNTA-related efficacy outcomes at T3 vs. T0 documented comparable improvements between AM vs. PM-treated patients. Safety/tolerability was also similar between groups. Conclusions: We were not able to identify significant differences between patients treated in the AM vs. PM, so as to demonstrate that the circadian time of administration should be considered before initiating BoNTA in CM patients. MDPI 2022-04-21 /pmc/articles/PMC9145697/ /pubmed/35622543 http://dx.doi.org/10.3390/toxins14050296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dermitzakis, Emmanouil V.
Vikelis, Michail
Vlachos, George S.
Argyriou, Andreas A.
Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title_full Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title_fullStr Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title_full_unstemmed Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title_short Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
title_sort assessing the significance of the circadian time of administration on the effectiveness and tolerability of onabotulinumtoxina for chronic migraine prophylaxis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145697/
https://www.ncbi.nlm.nih.gov/pubmed/35622543
http://dx.doi.org/10.3390/toxins14050296
work_keys_str_mv AT dermitzakisemmanouilv assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis
AT vikelismichail assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis
AT vlachosgeorges assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis
AT argyriouandreasa assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis